Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
{
"resourceType" : "Bundle",
"id" : "bundlepackageleaflet-en-9f9daf83bf13eb0a61dfb2c983d49142",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"
]
},
"language" : "en",
"identifier" : {
"system" : "http://ema.europa.eu/identifier",
"value" : "None"
},
"type" : "document",
"timestamp" : "2023-06-27T10:09:22Z",
"entry" : [
{
"fullUrl" : "Composition/composition-en-9f9daf83bf13eb0a61dfb2c983d49142",
"resource" : {
"resourceType" : "Composition",
"id" : "composition-en-9f9daf83bf13eb0a61dfb2c983d49142",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"
]
},
"language" : "en",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><a name=\"Composition_composition-en-9f9daf83bf13eb0a61dfb2c983d49142\"> </a><p class=\"res-header-id\"><b>Generated Narrative: Composition composition-en-9f9daf83bf13eb0a61dfb2c983d49142</b></p><a name=\"composition-en-9f9daf83bf13eb0a61dfb2c983d49142\"> </a><a name=\"hccomposition-en-9f9daf83bf13eb0a61dfb2c983d49142\"> </a><a name=\"composition-en-9f9daf83bf13eb0a61dfb2c983d49142-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html\">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/20/1523/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}\">Package Leaflet</span></p><p><b>category</b>: <span title=\"Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}\">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href=\"Organization-mah-ema.html\">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - ogluo</p><h3>Attesters</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://hl7.org/fhir/composition-attestation-mode official}\">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/20/1523/001"
}
],
"status" : "final",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package Leaflet"
},
"category" : [
{
"coding" : [
{
"system" : "http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs",
"code" : "R",
"display" : "Raw"
}
]
}
],
"subject" : [
{
"reference" : "MedicinalProductDefinition/mp9f9daf83bf13eb0a61dfb2c983d49142"
}
],
"date" : "2022-02-16T13:28:17Z",
"author" : [
{
🔗 "reference" : "Organization/mah-ema"
}
],
"title" : "TEST PURPOSES ONLY - ogluo",
"attester" : [
{
"mode" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/composition-attestation-mode",
"code" : "official"
}
]
},
"time" : "2022-02-16T13:28:17Z"
}
],
"section" : [
{
"title" : "B. Package Leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "B. Package Leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">unavailable</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "unavailable"
}
]
},
"section" : [
{
"title" : "Package leaflet: Information for the user",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package leaflet: Information for the user"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
}
},
{
"title" : "What is in this leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "What is in this leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What is in this leaflet</p><ol type=\"1\"><li>What Ogluo is and what it is used for</li><li>What you need to know before you use Ogluo</li><li>How to use Ogluo</li><li>Possible side effects</li><li>How to store Ogluo</li><li>Contents of the pack and other information</li></ol></div>"
}
},
{
"title" : "1. What ogluo is and what it is used for",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "1. What ogluo is and what it is used for"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Ogluo contains the active substance glucagon, which belongs to a group of medicines called glycogenolytic hormones.</p><p>It is used to treat severe hypoglycaemia (very low blood sugar) in people with diabetes. It is for use in adults, adolescents, and children aged 2 years or older.</p><p>Ogluo is a ready-to-use, pre-filled pen that contains a single dose of the active substance, glucagon. It is a subcutaneous injection, meaning that the medicine is administered under the skin using a needle.</p><p>Glucagon is a natural hormone produced by the pancreas, which has the opposite effect of insulin in the human body. It helps the liver to convert stored sugar in the liver called glycogen into glucose (sugar). Glucose is then released into the blood stream, which makes the blood sugar level rise, reducing the effects of hypoglycaemia.</p><p>Information on hypoglycaemia Early symptoms of hypoglycaemia (low blood sugar) include:</p><ul><li><p>sweating</p></li><li><p>drowsiness</p></li><li><p>dizziness</p></li><li><p>sleep disturbances</p></li><li><p>palpitation</p></li><li><p>anxiety</p></li><li><p>tremor</p></li><li><p>blurred vision</p></li><li><p>hunger</p></li><li><p>slurred speech</p></li><li><p>depressed mood</p></li><li><p>tingling in the hands, feet, lips, or tongue</p></li><li><p>irritability</p></li><li><p>light-headedness</p></li><li><p>abnormal behaviour</p></li><li><p>inability to concentrate</p></li><li><p>unsteady movement</p></li><li><p>headache</p></li><li><p>personality changes</p></li></ul><p>If not treated, the patient may progress to severe hypoglycemia which can include:</p><ul><li>confusion</li><li>seizures</li><li>unconsciousness</li><li>death</li></ul></div>"
}
},
{
"title" : "2. What you need to know before you take ogluo",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "2. What you need to know before you take ogluo"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Important information</p><ul><li><p>Make sure that you, your family members, people you work with, and close friends know about Ogluo. Tell them that if you show any signs of severe hypoglyecaemia, including confusion, seizures, or unconciousness (pass out) they should use Ogluo straight away. You should always carry Ogluo with you.</p></li><li><p>It is important that you or those around you know how to use Ogluo before you need it. Show your family members and others where you keep Ogluo and how to use it. They must act quickly if you become unconscious because if this happens for a period of time, it may be harmful. You, or the person administering Ogluo to you, should follow the instructions in Section 3 of this leaflet: How to use Ogluo .</p></li><li><p>It is important that you store Ogluo correctly to make sure that it can be used straight away if you need it. See Section 5 for more information on how to store this medicine properly.</p></li></ul><p>Do not use Ogluo if:</p><ul><li>You are allergic to glucagon or any of the other ingredients in this medicine (listed in Section 6).</li><li>You have a tumour in your adrenal gland (pheochromocytoma).</li></ul><p>Warnings and precautions<br/>Talk to your doctor, pharmacist, or nurse before using Ogluo.</p><p>Ogluo may not work properly if:</p><ul><li>You have been fasting or have had low blood sugar levels for a long time</li><li>You have low levels of adrenaline</li><li>You have low blood sugar caused by drinking too much alcohol</li><li>You have a tumour that releases glucagon or insulin</li></ul><p>If any of these apply to you, talk to your doctor or pharmacist.</p><p>Please take into account that approximately 15% of patients achieved glucose recovery after minutes or more in the pivotal trial.</p><p>After using Ogluo, eat as soon as possible to prevent the recurrence of low blood sugar. Take a fast- acting source of sugar, such as fruit juice or a sugar-containing carbonated drink.</p><p>Children Ogluo is not recommended for children under 2 years of age because it has not been studied in this age group.</p><p>Other medicines and Ogluo Tell your doctor if you are taking, have recently taken, or might take any other medicines.</p><p>The following medicines can affect the way that Ogluo works:</p><ul><li>Insulin used to treat diabetes. Insulin has the opposite effect of glucagon on blood sugar.</li><li>Indomethacin used to treat joint pain and stiffness. Indomethacin reduces the effect of glucagon.</li></ul><p>Ogluo can affect the way that the following medicines work:</p><ul><li>Warfarin used to prevent blood clots. Ogluo may increase the blood-thinning effect of warfarin.</li><li>Beta-blockers used to treat high blood pressure and irregular heart beat. Ogluo may increase your blood pressure and pulse but this will only last a short time.</li></ul><p>If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking Ogluo.</p><p>Pregnancy, breast-feeding and fertility If you experience very low blood sugar when you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, you can use Ogluo.</p><p>Ask your doctor or pharmacist for advice before taking any medicine if you are pregnant.</p><p>Driving and using machines After a severe hypoglycaemic event your ability to concentrate and react may be reduced, you should wait until the effects of very low blood sugar have worn off, and you feel better, before driving or using any tools or machines.</p></div>"
}
},
{
"title" : "3. How to take ogluo",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "3. How to take ogluo"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Always use (or give) this medicine exactly as described in this leaflet or as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Ogluo is given as an injection under the skin (subcutaneous injection). It is supplied in a pen. The injector pen contains a measured amount of medicine, so if you follow these instructions, the whole dose is administered.</p><p>Prepare</p><p>Check the expiry date printed on the pouch.</p><p>Important: Do not use this medicine if the expiry date has passed. If this medicine is expired, throw it away in accordance with local requirements and use a new one.</p><p>Tear open the pouch at the dotted line and remove the pen (see Figure 1).</p><p>Figure 1</p><p>Inspect the solution</p><p>Look at the liquid medicine through the viewing window. It must be clear and colourless, or a pale yellow (see Figure 2).</p><p>Important: Do not use this medicine or inject if the liquid is discoloured, contains lumps, flakes, or particles.<br/>Do not inject if solution is not visible in the viewing window.<br/>After injection, call for emergency medical help right away. Each pen contains a single dose of glucagon and cannot be reused.</p><p>Figure 2</p><p>Pull the red needle cap straight off of the device (see Figure 3).</p><p>Important: Do not put your thumb, fingers, or hand on or near the needle guard or needle opening to help prevent accidental needle sticks.</p><p>Figure 3</p><p>Inject</p><p>Choose injection site and expose bare skin.</p><p>Choose the lower abdomen, outer thigh, or outer upper arm for your injection site (see Figure 4).</p><p>Remove any clothing covering the injection site (see Figure 5). The injection must be performed straight into the skin.</p><p>Important: Do not inject through clothing.</p><p>Figure 4 Figure 5</p><p>Pull Off Red Cap</p><p>Front view Back view Expose skin of injection site</p><p>Push and hold this medicine straight down against the injection site. Listen for a click .</p><p>Continue to hold the device down and count slowly to 5 (see Figure 6).</p><p>When the injection is complete, the viewing window will be red (see Figure 7).</p><p>Important: Do not lift up this medicine until the injection is complete.</p><p>Figure 6 Figure 7</p><p>Lift the pen straight up from the injection site (see Figure 8).</p><p>The yellow needle guard will lock over the needle.</p><p>Figure 8</p><p>Assist</p><p>Turn patient onto side.</p><p>When an unconscious person wakes up, he or she may be sick (vomit). If the patient is unconscious, turn them on their side to prevent choking (see Figure 9).</p><p>Call for emergency medical help right after Ogluo has been injected. When the patient has responded to the treatment, give him/her a fast- acting source of sugar, such as fruit juice or a sugar-containing carbonated drink to prevent the recurrence of low blood sugar. If the patient does not respond within 15 minutes, an additional dose of Ogluo from a new device may be administered while waiting for emergency assistance.</p><p>Figure 9</p><p>How much to use This medicine contains either 0.5 mg or 1 mg of the active substance in a fixed dose of medicine. You will be prescribed the correct strength (dose) of medicine for your own personal use.</p><p>The recommended dose for adults, adolescents, and children is shown in the table below. For children under 6 years, the recommended dose will depend on how much they weigh.</p><p>Push and hold Hold down for 5 seconds Click</p><p>Lift away from skin Yellow needle guard locks over needle Roll onto side</p><p>Age Weight Recommended dose of Ogluo<br/>Children, ages 2 years to under 6 years Less than 25 kg</p><p>0.5 mg Children, ages 2 years to under 6 years More than or equal to 25 kg</p><p>1 mg Adults and adolescents,<br/>6 years and over Not Applicable 1 mg</p><p>After using this medicine, eat as soon as possible to prevent the recurrence of low blood sugar. Take a fast-acting source of sugar, such as fruit juice or a sugar-containing carbonated drink.</p><p>If you use more Ogluo than you should Too much medicine may make you feel sick (nausea) or cause you to be sick (vomit). Specific treatment is not usually necessary.</p></div>"
}
},
{
"title" : "4. Possible side effects",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "4. Possible side effects"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Contact your doctor or a healthcare professional immediately if you notice any of the following serious side effects:</p><p>Very rare (may affect up to 1 in 10,000 people)</p><ul><li>allergic reaction signs may include wheezing, sweating, rapid heartbeat, rash, swollen face (i.e, swelling of the face, lips, tongue, and throat which may cause difficulty in swallowing or breathing), or collapse. Allergic reaction has not been reported with Ogluo, but has been seen in other injectable glucagon medicines. You should seek help urgently if you experience symptoms of an allergic reaction.</li></ul><p>Other side effects may include: Very common (may affect more than 1 in 10 people)</p><ul><li>feeling sick (nausea)</li><li>being sick (vomiting)</li></ul><p>Common (may affect up to 1 in 10 people)</p><ul><li>headache</li><li>fast heartbeat (tachycardia)</li><li>discomfort or a reaction at the site of injection</li><li>injection site oedema (swelling)</li><li>diarrhoea</li></ul><p>Uncommon (may affect up to 1 in 100 people)</p><ul><li>abdominal pain</li><li>injection site bruising</li><li>injection site erythema (redness)</li></ul><p>Additional side effects in children</p><p>Common (may affect up to 1 in 10 people)</p><ul><li><p>hyperglycaemia</p></li><li><p>abdominal pain</p></li><li><p>urticaria (swelling/redness)</p></li><li><p>head injury</p></li><li><p>dizziness Reporting of side effects If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V.<br/>By reporting side effects, you can help provide more information on the safety of this medicine.</p></li></ul></div>"
}
},
{
"title" : "5. How to store ogluo",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "5. How to store ogluo"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Do not use this medicine after the expiry date which is stated on the pen, pouch, and carton. The expiry date refers to the last day of that month.</p><p>Keep this medicine out of the sight and reach of children.</p><p>This medicine should not be stored above 25 C.</p><p>Do not refrigerate or freeze. Do not store below 15 C.</p><p>Store in the foil pouch before use to protect from light and moisture.</p><p>Do not use this medicine if you notice the solution is discoloured or contains particulate matter.</p><p>Do not throw away any medicines via household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>"
}
},
{
"title" : "6. Contents of the pack and other information",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "6. Contents of the pack and other information"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What Ogluo contains</p><ul><li><p>The active substance in Ogluo is glucagon.</p></li><li><p>Ogluo 0.5 mg solution for injection in pre-filled pen<br/>Each pre-filled pen contains 0.5 mg glucagon in 0.1 mL.</p></li><li><p>Ogluo 1 mg solution for injection in pre-filled pen<br/>Each pre-filled pen contains 1 mg glucagon in 0.2 mL.</p></li><li><p>The other ingredients are trehalose dihydrate, dimethyl sulfoxide (DMSO), sulfuric acid, and water for injections.</p></li></ul><p>What Ogluo looks like and the contents of the pack Ogluo is a clear, colourless to pale yellow solution. It is produced in a ready-to-use, pre-filled, single- dose pen, containing either 0.5 mg or 1 mg of glucagon. Each medicine is indivudally packaged in a foil pouch. A full list of the available Ogluo medicines is provided below.</p><ul><li><p>Ogluo 0.5 mg solution for injection in pre-filled pen, pack of 1 or 2 single-dose pre-filled pens.</p></li><li><p>Ogluo 1 mg solution for injection in pre-filled pen, pack of 1 or 2 single-dose pre-filled pens.</p></li></ul><p>Not all pack sizes may be marketed.</p><p>Marketing Authorisation Holder: Tetris Pharma B.V Bargelaan Element Offices 2333 CW Leiden Netherlands</p><p>Manufacturer:<br/>Manufacturing Packaging Farmaca (MPF) B.V. Neptunus Heerenveen, 8448CN Netherlands</p><p>This leaflet was last revised in</p><p>Other sources of information</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>"
}
}
]
}
]
}
},
{
"fullUrl" : "MedicinalProductDefinition/mp9f9daf83bf13eb0a61dfb2c983d49142",
"resource" : {
"resourceType" : "MedicinalProductDefinition",
"id" : "mp9f9daf83bf13eb0a61dfb2c983d49142",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"MedicinalProductDefinition_mp9f9daf83bf13eb0a61dfb2c983d49142\"> </a><p class=\"res-header-id\"><b>Generated Narrative: MedicinalProductDefinition mp9f9daf83bf13eb0a61dfb2c983d49142</b></p><a name=\"mp9f9daf83bf13eb0a61dfb2c983d49142\"> </a><a name=\"hcmp9f9daf83bf13eb0a61dfb2c983d49142\"> </a><a name=\"mp9f9daf83bf13eb0a61dfb2c983d49142-en-US\"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/20/1523/001</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}\">Medicinal Product</span></p><p><b>domain</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-domain Human}\">Human use</span></p><p><b>status</b>: <span title=\"Codes:{http://hl7.org/fhir/publication-status active}\">active</span></p><p><b>legalStatusOfSupply</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi 100000072084}\">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Ogluo 0.5 mg solution for injection in pre-filled pen.</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}\">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}\">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}\">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}\">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}\">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:ietf:bcp:47 en}\">en</span></td></tr></table></blockquote></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/20/1523/001"
}
],
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-type",
"code" : "MedicinalProduct",
"display" : "Medicinal Product"
}
]
},
"domain" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-domain",
"code" : "Human",
"display" : "Human use"
}
]
},
"status" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/publication-status",
"code" : "active",
"display" : "active"
}
]
},
"legalStatusOfSupply" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi",
"code" : "100000072084",
"display" : "Medicinal product subject to medical prescription"
}
]
},
"name" : [
{
"productName" : "Ogluo 0.5 mg solution for injection in pre-filled pen.",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000001",
"display" : "Full name"
}
]
},
"part" : [
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000002",
"display" : "Invented name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000003",
"display" : "Scientific name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000004",
"display" : "Strength part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000005",
"display" : "Pharmaceutical dose form part"
}
]
}
}
],
"usage" : [
{
"country" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"jurisdiction" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"language" : {
"coding" : [
{
"system" : "urn:ietf:bcp:47",
"code" : "en",
"display" : "en"
}
]
}
}
]
}
]
}
}
]
}
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
